Shares of Nabriva Therapeutics Plc were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia. Nabriva plans to share more details from the open-label CF study in the first half of next year. The company's stock has tumbled 85.5% this year, while the broader S&P 500 is down 15.5%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.